Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products
Toxicologic Pathology · 2025-01 · 53 (1) · 31-44
DOI: 10.1177/01926233241311259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 28.01.2025. Verfasst von Axel Vicart und 14 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institute for Biomedical Research, Basel, Switzerland. Hauptthemen laut MEDLINE: Biological Products, Protein Array Analysis, Toxicity Tests. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Off-target evaluation is essential in preclinical safety assessments of novel biotherapeutics, supporting lead molecule selection, endpoint selection in toxicology studies, and regulatory requirements for first-in-human trials. Off-target interaction of a therapeutic antibody and antibody derivatives has been historically assessed via the Tissue Cross-Reactivity (TCR) study, in which the candidate molecule is used as a reagent in immunohistochemistry (IHC) to assess binding of the candidate molecule to a panel of human tissue sections. The TCR approach is limited by the performance of the therapeutic as an IHC reagent, which is often suboptimal to outright infeasible. Furthermore, binding of the therapeutic in IHC conditions typically has poor in vitro to in vivo translation and lacks qualitative data of the identity of putative off-targets limiting the decisional value of the data. More recently, cell-based protein arrays (CBPA) that allow for screening against a large portion of the human membrane proteome and secretome have emerged as a complement, and likely a higher value alternative, to IHC-based off-target assessment. These arrays identify specific protein interactions and may be useful for testing nontraditional antibody-based therapeutic formats that are unsuitable for TCR studies. This article presents an overview of CBPA technologies in the context of TCR and off-target assessment studies. Selected case examples and strategic considerations covering a range of different modalities are presented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Institute for Biomedical Research, Basel, Switzerland.
- Johnson & Johnson, Spring House, Pennsylvania, USA.
- Takeda US, Inc, Cambridge, Massachusetts, USA.
- Charles River Laboratories, Miserey, France.
- Charles River Laboratories, High Peak, UK.
- Johnson & Johnson, San Diego, California, USA.
ORCID-Profile: Axel Vicart, Mark Aspinall-O'Dea, Tim MacLachlan, Elizabeth Clark
Zitieren
APA
Vicart, A., Holland, C., Fraser, K., Gervais, F., Aspinall-O'Dea, M., Brown, N., Siddals, K., Greiner, G., Carreira, V., Galbreath, E., Willer, M., Kaliyaperumal, S., Wood, C., MacLachlan, T., & Clark, E. (2025). Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products. Toxicologic Pathology, 53(1), 31-44. https://doi.org/10.1177/01926233241311259
Vancouver
Vicart A, Holland C, Fraser K, Gervais F, Aspinall-O'Dea M, Brown N, et al. Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products. Toxicologic Pathology. 2025;53(1):31-44. doi:10.1177/01926233241311259
BibTeX
@article{Vicart2025,
author = {Vicart, Axel and Holland, Cam and Fraser, Kathryn and Gervais, Frederic and Aspinall-O'Dea, Mark and Brown, Nick and Siddals, Kirk and Greiner, Géraldine and Carreira, Vinicius and Galbreath, Elizabeth and Willer, Maggie and Kaliyaperumal, Saravanan and Wood, Charles and MacLachlan, Tim and Clark, Elizabeth},
title = {Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products},
journal = {Toxicologic Pathology},
year = {2025},
volume = {53},
number = {1},
pages = {31--44},
doi = {10.1177/01926233241311259}
}
EUVIMED